("4basebio" or the "Company")
Director Dealings
Further details are set out in the Notification of Dealing Form below.
Shareholding
Shareholding Following
Director / PCA Number of Ordinary Purchase Price Following Acquisition as a
Shares Acquired (Aggregated) (p) Acquisition Percentage of
Issued Share
Capital
Dr. Heikki 3,000 575.82 1,122,688 7.23%
Lanckriet
Mr Hansjörg 1,000 585.00 7,667† 0.05%†
Plaggemars*
* Purchase was made by Mr Plaggemars , on behalf of his wife.
†Aggregate shareholding of Mr Plaggemars and persons closely associated with
him.
The 3,000 and 1,000 additional shares purchased represent approximately 0.02 per cent. and 0.01 per cent. of the Company's issued share capital, respectively.
The issued share capital of the Company comprises 15,538,518 ordinary shares.
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 as amended by regulation 11 of the Market Abuse (Amendment) (EU Exit) Regulations 2019/310.
For further enquiries, please contact:
4basebio PLC +44 (0)12 2396 7943
Dr Amy Walker , CEO
Cairn Financial Advisers LLP (Nominated Adviser) +44 (0)20 7213 0880
Jo Turner / Sandy Jamieson / Ed Downes
Cavendish Capital Markets Limited (Joint Broker) +44 (0)20 7220 0500
Geoff Nash / Nigel Birks RBC Capital Markets (Joint Broker) +44 (0)20 7653 4000
Kathryn Deegan / Matthew Coakes ICR Healthcare (Media and Investor Relations) +44 (0)203 707 5700
Mary-Jane Elliott / Jessica Hodgson
Notes to Editors
About 4basebio
4basebio (AIM: 4BB) is an innovation driven life biotechnology company focused on accelerating the development of advanced therapy medicinal products (ATMPs) through its high-performance synthetic DNA products and non-viral, cell targeting nucleic acid delivery platform. The Company’s objective is to become a market leader in the manufacture and supply of high-quality synthetic DNA products for research, therapeutic and pharmacological use as well as development of target specific non-viral vectors for the efficient delivery of payloads in patients.
Forward-looking statements
This announcement may contain certain statements about the future outlook for 4basebio. Although the directors believe their expectations are based on reasonable assumptions, any statements about future outlook may be influenced by factors that could cause actual outcomes and results to be materially different.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
_________________________________________________________________ |1 |Details of the persons discharging managerial responsibilities| | |/ person closely associated | |__|______________________________________________________________| | | |1) Dr. Heikki Lanckriet | |a)|Name | | | | |2) Mr Hansjörg Plaggemars | |__|_______________________________|______________________________| |2 |Reason for the notification | |__|______________________________________________________________| | | |1) Non-executive Director | |a)|Position/Status | | | | |2) Non-executive Director | |__|_______________________________|______________________________| |b)|Initial notification/ Amendment|Initial notification | |__|_______________________________|______________________________| |3 |Details of the issuer, emission allowance market participant, | | |auction platform, auctioneer or auction monitor | |__|______________________________________________________________| |a)|Name |4basebio plc | |__|_______________________________|______________________________| |b)|LEI |213800E2DX9EAIUNCB30 | |__|_______________________________|______________________________| | |Details of the transaction(s): section to be repeated for (i) | |4 |each type of instrument; (ii) each type of transaction; (iii) | | |each date; and (iv) each place where transactions have been | | |conducted | |__|______________________________________________________________| | |Description of the financial | | | | | | | |instrument, type of |Ordinary Shares | |a)| | | | |instrument |ISIN: GB00BMCLYF79 | | | | | | |Identification code | | |__|_______________________________|______________________________| |b)|Nature of the transaction |Acquisition of ordinary shares| |__|_______________________________|______________________________| | | | | | | | Price(s) Volume(s) | | | | | |c)|Price(s) and volume(s) |1) 575.82p 3,000 | | | | | | | |2) 585.00p 1,000 | | | | | |__|_______________________________|______________________________| | | |1) 3,000 | | |Aggregated information | | | | |2) 1,000 | |d)|- Aggregated volume | | | | |1) 575.82p | | |- Aggregated Price | | | | |2) 585.00p | |__|_______________________________|______________________________| |e)|Date of transaction |10 February 2026 | |__|_______________________________|______________________________| |f)|Place of transaction |London Stock Exchange | |__|_______________________________|______________________________|
